相关实验视频

Updated: Jan 14, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

一个小分子准LIC1,通过诱导自而抑制肺瘤生长

Jia-Luo Huang¹, Lei-Ming Wu¹, Shu-Qi Wu¹

¹School of Pharmaceutical Sciences, State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, P. R. China.

Nature chemical biology

|October 16, 2025

概括

研究人员发现了一种新型化合物,即奥克萨特罗尔A (DAA) 的3,4-二异巴基衍生物,它可以有效诱导自. 这种强大的自诱导剂显示出作为非小细胞肺癌 (NSCLC) 的抗癌疗法具有前途.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

通过小分子诱导自为化学探针和抗癌疗法提供了潜力.
非小细胞肺癌 (NSCLC) 仍然是治疗发展的重要领域.

研究的目的:

识别和描述诱导自的新型小分子.
评估在NSCLC中发现的化合物的治疗潜力.
阐明分子作用机制,并确定该化合物的直接目标.

主要方法:

选由内细胞衍生的小分子库. 小分子库.
照片亲和度标签用于识别直接的分子目标.
在体外和体内测试以评估抗瘤疗效和免疫治疗敏感性.
西方涂抹和分子相互作用研究,以调查信号通路.

主要成果:

鉴定了3,4-二异基衍生物的奥克萨特罗尔A (DAA) 作为一个强大的自诱导剂.
在NSCLC模型中,DAA表现出显著的抗瘤疗效,并使瘤对抗PD1免疫疗法的敏感.
轻中间链1 (LIC1) 是一种dynein子单元,被确定为DAA的直接目标.
在NSCLC中LIC1过度表达与生存率差相关.
DAA 破坏 LIC1 相互作用,激活 GCN2-eIF2α-ATF4 综合应激反应,促进自细胞死亡.

结论:

LIC1是一种新的NSCLC治疗点.
DAA是一种有前途的自诱导剂,有可能用于NSCLC治疗,特别是与免疫疗法结合使用.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...